PartⅡ Individual Analysis of Brain Tumor ( )

Transcript

1 6 PartⅡ Individual Analysis of Brain Tumor (98-000). Location of Tumor ) Location of Tumor Origin (98-000) oligodendoro- ependy- glioblas- medulloglioma* moma* toma astrocytoma* blastoma frontal lobe,688 (5.) 7 (57.6) 68 (9.7),00 (5.) 6 (0.9) temporal lobe,60 (6.5) 99 (.0) (.),99 (5.) (0.) parietal lobe 88 (.5) 75 (9.9) 5 (7.),05 (7.5) (0.6) occipital lobe 98 (.6) (.) (.) 9 (5.7) - (-) diffuse 88 (.) 5 (0.7) (0.) 7 (.) - (-) chiasmal region 6 (.5) (0.) (0.) 7 (0.) (0.) third ventricle, ant. 89 (.) (.7) 0 (.) (0.) (0.) third ventricle, post. 59 (0.8) (0.) 6 (0.9) 6 (0.) - (-) lat. vent. (ant. hornbody) 8 (.8) (5.7) 6 (9.0) 8 (0.5) (0.) lat. vent. (trigoum) 7 (0.5) (0.5) (.) (0.5) - (-) lat. vent. (temp. horn) 5 (0.) (0.) (0.6) 0 (0.) - (-) corpus callosim and septum pellucidum 60 (.) 7 (.) (0.) 76 (.0) (0.) rostral brain stem and basal ganglia 56 (6.9) (.7) (0.6) 77 (.7) - (-) pineal region 6 (0.6) (0.) 7 (.0) (0.) (0.) aqueduct (0.) - (-) (0.6) (0.0) - (-) cerebellar vermis 7 (.) - (-) 9 (5.6) (0.6) 8 (68.0) cerebellar hemisphere 79 (5.0) (0.) 5 (.6) 9 (.5) 6 (8.6) fourth ventricle (0.5) - (-) 58 (6.9) 6 (0.) 6 (7.8) cerebello- pontine 0 (0.) 6 (0.8) (.) 7 (0.) 6 (0.9) angle caudal brain stem(pons 5 (5.6) (0.) (.) 86 (.) 9 (.) and medulla) optic nerve 80 (.) - (-) - (-) (0.) - (-) calvarium 9 (0.) (0.) - (-) 6 (0.) (0.) skull-base, medial 8 (0.) (0.) - (-) 8 (0.) - (-) skull-base, paramedial (0.0) (0.) (0.) (0.0) - (-) others 9 (.) 6 (0.8) 6 (5.) 8 (.) 6 (0.9) 7,66 (00.0) 759 (00.0) 699 (00.0) 5,96 (00.0) 707 (00.0) * malignant cases included 5

2 7 ) Supra or Infratentorial astrocytoma * oligodendoro- ependy- glioblas medullomeningioma glioma moma toma blastoma supratentorial 6,90 (8.) 595 (98.) 09 (0.9) 5,7 (95.) 8 (.5),606 (79.) infratentorial,7 (5.) 8 (.) 85 (55.8) (.7) 670 (9.5),686 (5.6) supra & infra 6 (.6) (0.) 7 (.) 7 (.) (.0) 9 (5.) 7,687 (00.0) 605 (00.0) 5 (00.0) 6,05 (00.0) 709 (00.0) 7,06 (00.0) others * malignant astrocytoma included ) Laterality astrocytoma * oligodendoro- ependy- glioblas- medullo glioma moma toma blastoma meningioma right,98 (8.6) 66 (.) 0 (9.7),68 (.0) (5.0) 6,878 (0.) left,96 (8.) 7 (9.) 00 (9.),505 (.) 6 (5.) 7,05 (.) bilateral 75 (9.8) 57 (9.5) 6 (8.9) 6 (0.5) 76 (.),666 (9.8) central,09 (.) (7.) 70 (5.) 0 (.5) 58 (78.7),77 (8.7) 7,6 (00.0) 60 (00.0) 58 (00.0) 5,956 (00.0) 68 (00.0) 7,07 (00.0) others * malignant astrocytoma included Part II. Frequency of Tumors in Special Sites ) Frontal Lobe ) Parietal Lobe glioblastoma,00 (.) glioblastoma,05 (.) astrocytoma,5 (.6) astrocytoma 57 (8.) anapl. astrocytoma,6 (7.6) anapl. astrocytoma (6.8) * 7 (6.7) * 75 (.0) ependymoma * 68 (.0) ependymoma * 5 (.0) mixed glioma 0 (.) hemangiopericytoma 6 (0.) germinoma 6 (0.) malig. lymphoma 0 (8.) malig. lymphoma 9 (7.6) other sarcoma (0.) others sarcoma 8 (0.) others 5 (0.) others 9 (7.6),57 (00.0) 6,57 (00.0) 86 5 ) Temporal Lobe ) Occipital Lobe glioblastoma,99 (.) glioblastoma 9 (.6) astrocytoma 699 (9.6) astrocytoma 0 (.7) anapl. astrocytoma 56 (5.7) anapl. astrocytoma 97 (.) ependymoma * (0.6) ependymoma * (.9) 99 (.8) * (.0) ganglioglioma 69 (.9) neurinoma (0.) neurinoma 0 (0.6) malig. lymphoma 96 (.) mixed glioma (.) other sarcoma 5 (0.6) epidemoid (0.9) others 0 (.8) malig. lymphoma 0 (5.6) 796 (00.0) other sarcoma 9 (0.) others 07 (8.6),56 (00.0) Since meningioma is classified in special site 09 (e.g. convexity or parasagittal ), number of patients * malignant cases included with meningioma is excluded here.

3 8 5) Lateral Ventricle 6) Pituitary Grand-Chiasmal Region ependimoma * 6 (0.8) pituitary adenoma * 8,8 (76.) * (7.) craniopharyngioma,7 (5.7) plexus papiloma * 0 (.) germinoma 05 (.8) astrocytoma 0 (7.) astrocytoma 0 (.0) anapl. astrocytoma 7 (6.) anapl. astrocytoma (0.) glioblastoma 8 (.8) teratoma * 0 (0.) mixed glioma 5 (0.9) epidermoid 9 (0.) epidermoid (0.7) chordoma * (0.) neurinoma * (schwannoma) (.) dermoid 6 (0.) malig. lymphoma (5.5) others 5 (.) other sarcoma (0.5) 0,978 (00.0) others 7 (0.5) 585 (00.0) 6 8) Rostal Brain Stem, Basal Ganglia 7) Third Ventricle and Aqueduct astrocytoma (.8) astrocytoma (.) glioblastoma 9 (.6) glioblastoma 78 (9.8) germinoma 86 (0.6) germinoma 99 (7.) ependymoma * 6 (.0) ependymoma * 8 (0.6) anapl. astrocytoma 6 (.) anapl. astrocytoma 5 (6.7) craniopharyngioma 69 (.) craniopharyngioma 5 (0.) teratoma * (.6) teratoma * (0.) 5 (.9) * (0.9) pineoblastoma (0.) pituitary adenoma * (0.8) pituitary adenoma * 8 (5.9) malig. lymphoma 8 (7.0) malig. lymphoma 9 (.6) others 00 (.) others 8 (8.),0 (00.0) 8 (00.0) 0 * malignant cases included

4 9 9) Caudal Brain Stem 0) Cerebellum and Fourth Ventricle neurinoma * 9 (0.9) 9 (0.9) astrocytoma 8 (7.7) hemangioblastoma 70 (6.8) ependymoma * (.) anapl. astrocytoma (.8) epidermoid (.) glioblastoma 86 (8.) von reckinghausen 9 (0.9) polar spongioblas (0.) glioma(not verified) 0 (.5) neuroblastoma (0.) chordoma * (.) others (.8),05 (00.0) (0.0) astrocytoma 55 (5.7) hemangioblastoma 9 (8.) ependymoma * (9.6) anapl. astrocytoma (.) glioblastoma (.0) epidermoid 85 (.5) plexus papilloma * 86 (.6) malig. lymphoma (.) neurinoma * 9 (0.9) neuroblastoma 7 (0.5) medulloepithelioma 8 (0.) others 9 (7.),6 (00.0) 7 Part II ) Cerebello-Pontine Angle ) Pineal Region neurinoma * 6,05 (88.6) epidermoid (6.0) von reckinghausen 97 (.) astrocytoma 8 (0.) anapl. astrocytoma (0.) glioblastoma 7 (0.) others (.) 6,8 (00.0) 9 * malignant cases icluded male female germinoma pineocytoma pineoblastoma teratoma malig. teratoma craniopharyngioma dermoid epidermoid others glioma(not verified) (6.6) (8.0) (5.) (.9) (.9) (0.) (0.) (.) (8.) (0.),08 8,56 (00.0) 89

5 0. Extension of Tumors one side,570 (56.9),697 (56.) 70 (6.7) 90 (56.6) 00 (9.6) 0 (5.0),87 (56.9) (6.) ventricular system 55 (.) 9 (.9) 88 (.7) 8 (.) 85 (6.) 5 (.8) 90 (5.6) 5 (5.9) central 595 (.) (.0) 65 (0.8) 5 (5.7) 89 (7.5) (0.6) 77 (.0) 9 (7.) opposite side 90 (6.) 79 (9.) 56 (9.) 8 (.) (.) (6.9) 650 (0.9) (.0) supra + infratentorial 58 (.) 7 (.6) (0.) (0.6) 9 (.8) (0.6) 56 (0.9) 0 (.9) other 9 (9.9) 57 (5.) 0 (.) 7 (.) 6 (.7) (.) 57 (.6) 75 (5.5),55 5 (00.0)),0 (00.0)) 600 (00.0)) 59 (00.0)) (00.0)) 60 (00.0)) 5,95 (00.0)) 686 (00.0)) Brain Tumor Patients with Other Malignant Tumors primary p y tumor all primary tumor neurinoma von Recklinghausen's origin of disease second tumor no double tumor 65,0 (96.6) 6,606 (96.8) 9 (5.) other organ tumor,66 (.5) (.6) 7 (.) CNS 67 (0.9) 05 (.5) 7 (.8) 67, (00.0) 6,8 (00.0) 70 (00.0) Macroscopic Features of Tumors (98-000) ) Character astrocytoma medullo- blastoma anapl. oligodendro- anapl. oligoastrocytoma glioma dendroglioma anapl. astrocytoma ependymoma glioblastoma ependymoma ependymoma glioblastoma meningioma solid,659 (59.7) 5 (58.) 5 (9.),78 (65.) (6.),59 (8.0) diffuse cystic (9.5) 5 (9.0) (6.5),009 (7.) 9 (.) 8 (0.5) circum- solid 88 (9.8) 5 (5.8) 67 (50.9) 669 (.6) 05 (.0) 5, (90.0) scribed cystic 88 (.0) (6.9) 7 (.5) 8 (5.7) 8 (5.5) 7 (.6),5 (00.0) 59 (00.0) 55 (00.0) 5,790 (00.0) 69 (00.0) 7,055 (00.0)

6 ) Infiltration astrocytoma ependymoma glioblastoma meningioma none,668 (9.5) 8 (9.) 0 (85.9),5 (8.) 55 (7.6) 6,0 (.7) arachnoid 56 (6.5) 0 (7.6) 57 (.) 6 (.) 8 (.) 5 (.8) dura 5 (0.9) 6 (.) 9 (.9) 7 (.) 7 (.) 7, (8.) skull 5 (0.) (0.) - (-) (0.) - (-),0 (7.) scalp - (-) - (-) - (-) - (-) - (-) 0 (0.),96 (00.0) 59 (00.0) 68 (00.0) 5, (00.0) 60 (00.0) 5,8 (00.0) nos , nos : not otherwise specified Part II ) Extracranial Metastasis or Dissemination astrocytoma ependymoma glioblastoma meningioma none,69 (97.) 56 (98.) 76 (95.0) 5,50 (97.) 5 (79.) 6,60 (98.9) spinal cord 07 (.) (.9) (.6) (.) 6 (9.) 9 (0.9) other 6 (0.) - (-) (0.) 9 (0.) 0 (.5) 9 (0.),8 (00.0) 575 (00.0) 50 (00.0) 5,65 (00.0) 650 (00.0) 6,78 (00.0) ) Diameter of Tumors < 0.5 cm >8 astrocytoma ependymoma glioblastoma meningioma 8 (.0) 0 (.9) (.5) 88 (.6) 9 (.) 00 (.) 55 (6.) (.) 5 (5.) 8 (0.9) 8 (.) 67 (.) 85 (.) 7 (.7) 9 (9.0) 59 (6.6) 67 (0.5),9 (9.7),86 (9.) 8 (.) (9.),69 (.5) (7.7),67 (8.) 800 (9.8) 0 (.) (.),596 (9.) 0 (.8),7 (0.8) 78 (.8) 87 (6.) 8 (9.9),86 (.8) 8 (.0),7 (.) 8 (.5) (7.9) 7 (5.6) 56 (0.) 5 (.),06 (6.5) 56 (.) (.) 8 (.7) 6 (.7) (0.) 6 (.) 6 (.6) 9 (5.5) 7 (.5) 7 (5.0) 5 (0.8) 8 (.8),07 (00.0) 5 (00.0) 8 (00.0) 5,8 (00.0) 60 (00.0) 6,6 (00.0) ,9

7 6. Performance State (Evaluation of Before and After Treatment) ) Before Treatment (98-000) astrocytoma ependymoma glioblastoma astrocytoma oligodendrogliomblastoma adenoma medullo- pituitary ependymoma glioblastoma meningioma pontine glioma,8 (6.) 6 (5.5) (6.) 790 (.) 0 (.0),007 (6.) 9 (.0) 9,67 (79.5),09 (.6) 7 (.) (.),08 (7.) 78 (5.5),09 (8.) 5 (.0),590 (.5) 56 (0.0) 56 (9.5) 50 (9.5) 878 (.9) 78 (.), (6.6) 9 (.) 5 (.7) 9 (0.8) 5 (8.6) 68 (.9),6 (.) (6.),09 (6.0) 7 (.0) (.) 5 8 (.) 0 (.7) 7 (.) 59 (0.) 0 (5.7) 96 (.) 55 (7.7) 5 (0.) 6 6 (.0) (.0) (.5) 600 (0.) 8 (.6) 6 (.5) 65 (9.) 66 (0.6) 7 56 (.) 8 (.) (.5) 599 (0.) 8 (5.5) 7 (.) 7 (0.0) 89 (0.8) blank 9 (0.6) (0.) - (-) 56 (0.9) (0.) 55 (0.9) 6 (.) 6 (0.5),56 (00.0) 59 (00.0) 59 (00.0) 5,899 (00.0) 697 (00.0) 7,099 (00.0) 78 (00.0),777 (00.0) meningioma pontine glioma pituitary adenoma,757 (8.) 77 (6.5) 5 (8.9) 76 (.8) 5 (7.8) 9,7 (5.0) 69 (9.6) 8,08 (67.6),8 (8.) 70 (8.5) (7.0),75 (.5) 7 (.8),66 (6.8) 68 (.),889 (.) 7 (0.) 7 (7.9) 66 (.5) 85 (.) 8 (.8),6 (7.9) 6 (7.5) 9 (.) 65 (.) 59 (9.9) 8 (5.),86 (.) 8 (9.7),5 (8.8) 09 (9.) (.6) 5 99 (.) 0 (.) (8.) 60 (0.5) 0 (.7) (.0) 67 (9.) 7 (0.6) 6 77 (.9) 0 (.) (6.) 79 (8.) 6 (9.) 7 (.) 69 (9.6) 76 (0.6) 7 8 (0.6) (0.5) 0 (.9) 8 (.) 5 (.) (0.) 0 (.) 5 (0.0),570 (00.0) 596 (00.0) 50 (00.0) 5,9 (00.0) 70 (00.0) 7,7 (00.0) 78 (00.0),86 (00.0) ) After Treatment (98-000). Normal; No complaints ; No evidence of disease. Normal activity with efforts; Some symptoms. Cares for self; Unable to carry on normal activity. Requires occational assistance; Cares for most needs 5. Disabled; Requires special care and assistance 6. Severely disabled; Hospitalized, death not imminent 7. Moribund; Fetal processes are rapidly progressing 9. Unknown

8 7. Pituitary Adenoma (98-000) ) Age Distribution male female 0 - (0.) (0.0) (0.0) (0.) 7 (0.) (0.) 0 - (0.9) 8 (0.7) 9 (0.8) (.5) 80 (.) 08 (.) 0-99 (.9) 68 (9.) 87 (6.9) (5.) 695 (0.) 96 (8.0) 0 - (6.7) 5 (7.6) 867 (7.) (8.6) 50 (7.7) 969 (8.) (9.9) 59 (8.6),098 (9.) (.0) 700 (0.),6 (0.6) (.0) 675 (9.8),89 (0.8) (.6) 65 (9.5), (0.) (0.8) 580 (8.5),8 (9.) (8.6) 90 (7.) 90 (7.8) (5.) 0 (.) 568 (.8) (.) (.8) (.9) (0.5) 5 (0.) 5 (0.) (0.) (0.0) 7 (0.) (-) (0.0) (0.0) (-) - (-) - (-) 5,096 (00.0) 6,855 (00.0),95 (00.0) 6 05 Part II ) Radiotherapy (98-000) mode male female none, (87.5) 6,05 (90.8) 0,69 (89.) Co (.9) 7 (.5) 70 (.) Linac (8.) (6.) 86 (7.) β-tron - (-) (0.0) (0.0) Heavy particle - (-) - (-) - (-) Isotope - (-) - (-) - (-) others (0.) 8 (0.) (0.) 5,065 (00.0) 6,8 (00.0),897 (00.0)

9 8. Pontine Glioma * (98-000) Age Distribution male female 0-9 (.8) 7 (.7) 96 (.) (.5) (.) 08 (8.6) 0 - (8.6) 0 (.6) 7 (0.0) (7.0) 6 (7.6) 5 (7.) 0 - (5.7) 8 (.) 0 (.) (6.8) (6.) 7 (6.5) 0-8 (.7) (.) (.) 5-9 (6.0) (.) (.7) 0 - (.) (.) (.) (.) 9 (.6) 5 (.) (.7) 0 (.9) 8 (.8) (.7) (.5) 0 (.) 60-6 (.) 8 (.) 0 (.7) (.) 7 (.0) 6 (.) 70-7 (0.5) 6 (.7) 8 (.) (.0) - (-) (0.5) (-) - (-) - (-) (0.) - (-) (0.) (-) - (-) - (-) (-) - (-) - (-) 8 (00.0) (00.0) 78 (00.0) * Pathologocally cases included